The efficacy as a biomarker of antibodies to NR2A/B (NMDA subunits) was evaluated in 205 patients with stroke (ischemic and haemorrhagic) and TIA and in 255 controls (with risk and non-risk factors). The gene discussed is GRIN2A; the disease is stroke disorder.